Euroopa Liit - itaalia - EMA (European Medicines Agency)

takeda gmbh - pantoprazolo - reflusso gastroesofageo - gli inibitori della pompa protonica - trattamento a breve termine dei sintomi da reflusso (e. bruciore di stomaco, rigurgito acido) negli adulti.

Euroopa Liit - itaalia - EMA (European Medicines Agency)

takeda gmbh - pantoprazolo - reflusso gastroesofageo - gli inibitori della pompa protonica - trattamento a breve termine dei sintomi da reflusso (e. bruciore di stomaco, rigurgito acido) negli adulti.

Euroopa Liit - itaalia - EMA (European Medicines Agency)

takeda gmbh - pantoprazolo - reflusso gastroesofageo - gli inibitori della pompa protonica - trattamento a breve termine dei sintomi da reflusso (e. bruciore di stomaco, rigurgito acido) negli adulti.

Euroopa Liit - itaalia - EMA (European Medicines Agency)

intervet international b. v. - tepoxalin - sistema muscoloscheletrico - cani - riduzione dell'infiammazione e sollievo dal dolore causato da disturbi muscoloscheletrici acuti e cronici.

Euroopa Liit - itaalia - EMA (European Medicines Agency)

zoetis belgium sa - mavacoxib - antinfiammatorio e antireumatico prodotti - cani - per il trattamento del dolore e dell'infiammazione associati a malattia degenerativa delle articolazioni nei cani nei casi in cui sia indicato un trattamento continuo superiore a un mese.

Euroopa Liit - itaalia - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - emoglobinuria, parossistica - immunosoppressori selettivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Itaalia - itaalia - AIFA (Agenzia Italiana del Farmaco)

hikma farmaceutica (portugal) s.a. - irinotecan - irinotecan

Itaalia - itaalia - AIFA (Agenzia Italiana del Farmaco)

teva italia s.r.l. - irinotecan - irinotecan

Itaalia - itaalia - AIFA (Agenzia Italiana del Farmaco)

sandoz gmbh - irinotecan - irinotecan

Itaalia - itaalia - AIFA (Agenzia Italiana del Farmaco)

docpharma n.v. - irinotecan - irinotecan